The cardiovascular crisis and a smarter solution through drug repurposing
Cardiovascular disease (CVD) remains the world's leading cause of death, claiming an estimated 17.9 million lives each year2 .
For decades, the pipeline for new heart medications has been dwindling, overshadowed by the high costs and lengthy timelines of developing drugs from scratch1 . But what if the key to fighting this global killer has been hiding in plain sight, nestled within our existing medicine cabinets?
This is the promise of drug repurposing—a strategy that finds new uses for existing, approved, or even abandoned drugs. It's a bit like discovering that a common household tool can perfectly fix a completely different, unexpected problem. This approach is transforming cardiovascular medicine, offering a faster, more cost-effective path to new treatments by breathing new life into old pills. By finding new roles for familiar drugs, scientists are not just accelerating the pace of discovery; they are opening a new, more precise front in the war against heart disease1 .
Developing a brand-new drug is a monumental task. It can take over a decade and cost billions of dollars, with no guarantee of success. Drug repurposing offers a smarter shortcut.
Because these drugs have already been tested for safety in humans, they can bypass many early-stage clinical trials, slashing both development time and financial risk1 .
The safety profile, side effects, and manufacturing processes are already understood, which de-risks the development process considerably1 .
Drugs often have more than one effect. A medication designed for one target can have unexpected, beneficial "off-target" effects on another, revealing new therapeutic opportunities1 .
Historically, many repurposing successes were happy accidents. The most famous example is sildenafil (Viagra), originally developed for angina (chest pain) but now a blockbuster for erectile dysfunction1 .
Gone are the days of relying solely on chance observations. Scientists now use a high-tech toolkit to systematically match old drugs to new cardiovascular indications.
Researchers can now analyze the vast "genetic signature" of a disease and compare it to the genetic changes a drug induces. The goal is to find a drug whose effects can reverse the disease's signature, like finding the right key for a lock1 .
By sifting through the digital records of millions of patients, artificial intelligence (AI) can spot unexpected patterns—for instance, that people taking a certain drug for condition A also have a much lower risk of developing heart disease1 2 .
Realistic disease models, including heart cells grown from human stem cells and zebrafish, are used to rapidly screen thousands of existing drugs for their ability to correct disease-related abnormalities1 .
These methods have led to some of the biggest recent breakthroughs in cardiology. A stellar example is the class of SGLT2 inhibitors, developed for type 2 diabetes. Through clinical trials, researchers discovered they were also remarkably effective at reducing hospitalizations and deaths from heart failure, a benefit that goes far beyond their blood sugar-lowering effects. They are now a standard of care for many heart failure patients1 6 .
To see how this works in practice, let's examine the fascinating case of probenecid, a decades-old drug used to treat gout. Recent research suggests it could be a powerful new weapon against heart damage following a heart attack7 .
Objective: To determine if probenecid could improve heart function and reduce detrimental remodeling after an induced heart attack (myocardial infarction) in an animal model.
The results were clear. The mice treated with probenecid showed significantly better outcomes than the untreated control group.
The data shows that probenecid treatment led to a statistically significant improvement in the heart's pumping ability (ejection fraction), prevented the heart from dilating and enlarging (a harmful process called remodeling), and reduced the size of the permanent scar. Crucially, it also lowered inflammation, which is a key driver of post-heart attack damage. This suggests probenecid isn't just masking symptoms—it is modifying the disease process itself7 .
The secret to probenecid's new talent lies in its newly discovered molecular targets. Beyond its original use, it is now known to:
| Reagent / Tool | Primary Function | Application in Repurposing |
|---|---|---|
| Induced Pluripotent Stem Cells (iPSCs) | Generate human heart cells in a dish from a patient's skin or blood cells. | Used to screen drug libraries and test efficacy on human cells carrying specific disease mutations1 . |
| Animal Models (e.g., Mouse, Zebrafish) | Provide a whole-organism system to study disease progression and drug effects. | Crucial for testing a repurposed drug's ability to improve function and survival in a living heart1 . |
| RNA Sequencing (RNA-seq) | Measures the level of all genes being expressed in a cell or tissue. | Used to create "gene expression signatures" of disease and drug response for computational matching2 . |
| Pannexin-1 Antibody | A reagent that specifically detects and measures the Pannexin-1 protein. | Used in experiments (like the probenecid study) to confirm the drug is hitting its intended target7 . |
The future of cardiovascular drug discovery is not just about repurposing in isolation. It's about convergence with other cutting-edge fields.
Machine learning algorithms are now able to analyze ECGs to detect subtle signs of heart disease long before symptoms appear and can even predict an individual's risk of future events6 .
For inherited conditions like familial hypercholesterolemia, CRISPR offers the potential for a one-time, curative therapy by correcting the faulty gene at its source. Early-phase trials for conditions like transthyretin amyloidosis are already showing promise6 .
Advances in pharmacogenomics are enabling treatments tailored to an individual's genetic makeup, increasing efficacy while reducing side effects of cardiovascular medications.
| Drug | Original Indication | Repurposed Cardiovascular Indication | Key Trial Finding |
|---|---|---|---|
| SGLT2 Inhibitors | Type 2 Diabetes | Heart Failure | Reduced heart failure hospitalizations by ~30%1 6 . |
| Colchicine | Gout Prevention | Acute Coronary Syndrome | Reduced major adverse cardiac events after a heart attack1 7 . |
| GLP-1 Receptor Agonists | Type 2 Diabetes | Cardiovascular Risk Reduction in Obesity | Showed a 20% reduction in major adverse cardiovascular events6 . |
Drug repurposing represents a paradigm shift in how we approach cardiovascular medicine. It is a strategy that is both pragmatic—saving time and money—and profoundly hopeful. By looking at our existing arsenal of medicines with fresh eyes and powerful new technologies, we can find novel solutions to one of humanity's oldest health threats.
This journey from serendipity to strategy is accelerating the delivery of better treatments to patients and bringing us closer to a world where the devastating impact of cardiovascular disease is a thing of the past.